Alphapharm Pty Ltd v H Lundbeck A/S and Ors

Link copied
Case Copied 21 min read

[2014] HCATrans 079

IN THE HIGH COURT OF AUSTRALIA

Office of the Registry
  Sydney   No S300 of 2013

B e t w e e n -

ALPHAPHARM PTY LTD ACN 002 359 739

Applicant

and

H LUNDBECK A/S

First Respondent

COMMISSIONER OF PATENTS

Second Respondent

ASPEN PHARMA PTY LTD ACN 075 449 594

Third Respondent

SANDOZ PTY LTD ACN 075 449 553

Fourth Respondent

APOTEX PTY LTD ACN 096 916 148

Fifth Respondent

Application for special leave to appeal

KIEFEL J
KEANE J

TRANSCRIPT OF PROCEEDINGS

AT SYDNEY ON FRIDAY, 11 APRIL 2014, AT 11.06 AM

Copyright in the High Court of Australia

____________________

MR D.K. CATTERNS, QC:   May it please the Court, I appear with my learned friends, MR C. DIMITRIADIS and MR J.S. ZMOOD, for the applicant and the fourth respondent.  (instructed by King & Wood Mallesons).

MS K.J. HOWARD, SC:   If the Court pleases, I appear with MR R.M. NIALL, SC, for the first respondent.  (instructed by Corrs Chambers Westgarth Lawyers)

KIEFEL J:   Yes, Mr Catterns.

MR CATTERNS:   If it is convenient to the Court, I was going to deal first with the question of unreasonableness and discretion.  My learned friend, Mr Dimitriadis, was going to follow, on the power to extend the time.

KEANE J:   Yes, that is no job for a gentleman, is it?

MR CATTERNS:   Well, your Honour, there is a ‑ ‑ ‑

KEANE J:   ‑ ‑ ‑ or a gentle lady for that matter.

MR CATTERNS:   ‑ ‑ ‑ there is a complex question of construction of the regulation which Mr Dimitriadis is the man for your Honour.

KEANE J:   Rank has some privileges.

MR CATTERNS:   Yes, your Honour. 

KIEFEL J:   It is very good of you to take on the more difficult question.

MR CATTERNS:   Well, thank you, your Honour.  So, your Honour, our submission is that it was manifestly unreasonable to grant a 10 year extension of time, in this statutory context, when the person who sought the extension, our friends from Lundbeck, knew there was an alternative course for four years and chose not to take it and it did so for reasons that included commercial reasons.  Its other reason was it adhered to its point of view, which was reasonably held, in the face of a series of findings to the contrary. 

Your Honours, of course, as the court explained in Li, the standard of reasonableness is indicated by the true construction of the statute.  Here that is section 223 and if I could go to that, and just remind your Honours this is a significant – it is in the combined authorities bundle, your Honours, at page 284 – this is a provision that has parallel provisions, almost word for word, in the Trade Marks Act and the Designs Act and it is a provision that is frequently invoked and, in a range of circumstances, ranging from the relatively unimportant to here, the extension of the term of time to apply for an…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Alphapharm Pty Ltd v H Lundbeck A/S and Ors and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] HCATrans 79
Decision Date

CaseChat Overview and Summary

Alphapharm Pty Ltd (Alphapharm) sought to import and sell a generic version of the antidepressant drug citalopram, the active ingredient of which was Lundbeck's patented drug Cipramil. Lundbeck, the patent holder, and its Australian subsidiary, H. Lundbeck A/S, sought to prevent Alphapharm from importing and selling its generic product. The dispute ultimately came before the High Court of Australia.

The central legal issue before the High Court was whether Alphapharm's proposed importation and sale of its generic citalopram product would infringe Lundbeck's Australian patent. This involved a determination of the scope of Lundbeck's patent claims and whether Alphapharm's product fell within that scope. A further issue concerned the interpretation of certain provisions of the Patents Act 1990 (Cth) relating to the infringement of pharmaceutical patents.

The High Court considered the construction of Lundbeck's patent claims, particularly in light of the doctrine of equivalents. Their Honours applied established principles of patent law, including the approach to claim construction and the assessment of infringement. The Court analysed the evidence regarding the chemical composition and therapeutic effect of both Lundbeck's and Alphapharm's products to determine if Alphapharm's product was equivalent to the patented invention. The Court found that Alphapharm's product did not infringe Lundbeck's patent.

The High Court ordered that Alphapharm's appeal be allowed and that the orders of the Full Federal Court be set aside. The Court declared that Alphapharm's proposed importation and sale of its citalopram product did not infringe Lundbeck's patent.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.